HMG (Human Menopausal Gonadotropin) — Research Overview
Chemical Name: Human Menopausal Gonadotropin (hMG) Also Known As: HMG, hMG, menotropins, Pergonal (original brand), Menopur, Menogon, Repronex Source: Urinary extract from the urine of postmenopausal women, which contains elevated levels of FSH and LH due to the loss of negative feedback from ovarian estrogen and inhibin at menopause Composition: Preparations containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity, classically in approximately a 1:1 ratio of 75 IU FSH to 75 IU LH per ampule, though specific ratios vary by product and formulation. Modern highly purified hMG (HP-hMG) preparations retain both FSH and LH activity at high purity while reducing urinary protein contamination. Historical Note: HMG was the first gonadotropin preparation used clinically for ovulation induction, introduced in the early 1960s by Bruno Lunenfeld, making it one of the longest-established clinical tools in reproductive medicine. FDA Approval Status: HMG preparations (menotropins) are FDA-approved for the induction of ovulation and pregnancy in anovulatory infertile women, and for stimulating multiple follicle development in women undergoing assisted reproductive technologies. They are also used in males for the induction of spermatogenesis in cases of hypogonadotropic hypogonadism. Category: Urinary gonadotropin / FSH and LH preparation / reproductive endocrinology research and clinical compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption outside of the specific FDA-approved indications described above when used in pharmaceutical-grade form. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is HMG?
Human menopausal gonadotropin is a biological preparation extracted and purified from the urine of postmenopausal women. At menopause, the ovaries cease responding to pituitary gonadotropin stimulation and cease producing estrogen and inhibin — the hormones that normally feed back to suppress FSH and LH secretion from the pituitary. In the absence of this feedback, the pituitary dramatically upregulates FSH and LH production, resulting in chronically elevated gonadotropin concentrations in menopausal urine. This urinary gonadotropin source forms the biological basis of HMG preparations.
HMG contains both FSH and LH biological activity, distinguishing it from FSH-only preparations. This dual activity reflects the physiological reality that both FSH and LH are required for normal folliculogenesis and steroidogenesis — a principle formalized as the two-cell, two-gonadotropin model of ovarian function. FSH acts on granulosa cells to drive follicle recruitment, growth, and aromatase activity, while LH acts on theca cells to provide the androgen precursors that granulosa cells convert to estrogens, and later triggers ovulation and luteinization. In male reproductive biology, FSH acts on Sertoli cells to support spermatogenesis while LH (and its functional analog hCG) acts on Leydig cells to drive testosterone production essential for sperm development.
HMG was first used clinically in the early 1960s by Bruno Lunenfeld, marking the beginning of gonadotropin-based ovulation induction therapy. It remains one of the most extensively studied and longest-established compounds in clinical reproductive medicine, with decades of randomized controlled trial data across both female fertility and male hypogonadism applications. This clinical history distinguishes HMG from most other compounds in this research catalog.
The Two-Cell, Two-Gonadotropin Model
Understanding HMG’s research significance requires understanding why both FSH and LH are necessary for normal follicular development and steroidogenesis — the scientific foundation for using preparations that contain both activities.
In the ovarian follicle, the mature follicle consists of two distinct steroidogenic cell populations working in coordinated fashion. Theca cells express LH receptors and respond to LH by producing androgens — primarily androstenedione and testosterone — from cholesterol through the steroidogenic pathway. These androgens diffuse into the adjacent granulosa cells. Granulosa cells express FSH receptors and respond to FSH by expressing aromatase, the enzyme that converts theca-derived androgens into estrogens (predominantly estradiol). Estradiol is the primary steroid produced by the follicle and is essential for endometrial development, follicle maturation, LH surge triggering, and multiple downstream reproductive functions.
Neither cell type alone can complete the steroidogenic process. Theca cells without FSH-driven aromatase in granulosa cells produce androgens that accumulate rather than being converted to estrogen. Granulosa cells without LH-driven theca androgen substrate have insufficient precursor for estrogen production. This obligate cooperation between the two cell types is the mechanistic basis for the two-cell, two-gonadotropin model, and explains why women with profoundly suppressed LH (as occurs during GnRH agonist down-regulation protocols) may benefit from LH supplementation through HMG rather than FSH alone.
In males, the parallel principle applies: FSH acts on Sertoli cells to support spermatogenesis, while LH (or hCG) acts on Leydig cells to produce the intratesticular testosterone concentrations that are required for spermatogenesis at concentrations far exceeding those achievable by systemic testosterone administration. This is why testosterone replacement, while adequate for systemic virilization, does not restore fertility — and why gonadotropin therapy using combinations of hCG (for LH activity) and HMG or FSH (for FSH activity) is required to induce and maintain spermatogenesis in hypogonadotropic hypogonadism.
Mechanism of Action
FSH component: The FSH in HMG preparations binds FSH receptors (FSHR) on granulosa cells (in females) and Sertoli cells (in males), activating Gs protein-coupled signaling that raises intracellular cAMP through adenylyl cyclase. In granulosa cells, FSH receptor activation drives follicle recruitment and growth, aromatase gene expression, estradiol production from androgen precursors, inhibin production, and LH receptor expression in preparation for the ovulatory LH surge. In Sertoli cells, FSH drives the production of androgen-binding protein, inhibin B, and other paracrine factors essential for structurally and functionally supporting developing spermatids through spermatogenesis.
LH component: The LH activity in HMG preparations (which in many formulations derives substantially from hCG present in postmenopausal urine rather than from authentic LH, given hCG’s greater urinary excretion and structural similarity) binds LH/hCG receptors on theca cells (in females) and Leydig cells (in males). In theca cells, LH receptor activation drives androgen synthesis through activation of the steroidogenic acute regulatory protein (StAR) and cytochrome P450 enzymes. In Leydig cells, LH/hCG receptor activation drives testosterone biosynthesis, generating the high intratesticular testosterone concentrations required for normal spermatogenesis.
The combined FSH and LH activities work synergistically in both male and female reproductive tissue to produce complete gonadal stimulation — an effect that cannot be replicated by either gonadotropin alone in most clinical contexts.
Published Research
Study 1 — Randomized Controlled Trial: HMG vs HP-FSH in IVF — LH Activity and Clinical Outcomes
Authors: Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE Year: 1996 Journal: Human Reproduction (referenced via PubMed) PMID: 8671425 Full text: https://pubmed.ncbi.nlm.nih.gov/8671425/
This prospective randomized trial of 218 infertile couples (114 HMG group, 104 HP-FSH group) examined whether the LH activity of HMG preparations had adverse effects on IVF clinical outcomes compared to highly purified FSH — directly addressing a widely held clinical concern about LH in ovarian stimulation.
Ongoing pregnancy rate per started cycle was 33% in the HMG group versus 29% in the HP-FSH group — comparable between groups.
Clinical abortion rates were similar between groups (10% HMG versus 14% HP-FSH), and implantation rate was 30% in each group.
Some beneficial effects of HMG on fertilization rates and pre-embryo development were demonstrated compared to HP-FSH, which the authors proposed may be caused by differences in LH content and the composition of FSH isoforms between HMG and HP-FSH preparations.
The authors concluded that no detrimental effect of the LH activity of HMG on clinical IVF outcomes was found in GnRH agonist down-regulated normogonadotrophic women — directly contradicting the prevailing concern that LH in HMG preparations was disadvantageous in IVF cycles.
Study 2 — Meta-Analysis: HMG vs Recombinant FSH in IVF/ICSI — Clinical Pregnancy Rates
Authors: van Wely M, Westergaard LG, Bossuyt PMM, van der Veen F Year: 2003 Journal: Fertility and Sterility PMID: 14607553 Full text: https://www.fertstert.org/article/S0015-0282(03)02187-3/fulltext
This meta-analysis of six randomized controlled trials (2,030 women undergoing IVF or ICSI) compared the effectiveness of HMG and recombinant FSH following GnRH analogue down-regulation for controlled ovarian hyperstimulation, providing the most comprehensive comparison of clinical pregnancy outcomes between the two compound classes available at time of publication.
In all six included trials, the group treated with HMG had higher pregnancy rates than the recombinant FSH group.
Pooling the five trials using a long GnRH agonist protocol resulted in a statistically significantly higher clinical pregnancy rate for HMG compared with recombinant FSH (relative risk 1.22, 95% CI 1.03 to 1.44).
No statistically significant difference in ongoing pregnancy or live birth rate was found between HMG and recombinant FSH recipients (relative risk 1.20, 95% CI 0.99 to 1.45) — though the trend consistently favored HMG.
No differences were found in gonadotropin dose used, oocytes retrieved, miscarriage rate, or multiple pregnancy rate between groups.
The authors concluded that HMG resulted in higher clinical pregnancy rates than recombinant FSH in IVF/ICSI cycles after GnRH agonist down-regulation in a long protocol, and called for larger randomized trials using live birth as the primary endpoint to more precisely estimate the difference.
Study 3 — Male Hypogonadotropic Hypogonadism: HCG/HMG for Spermatogenesis Induction
Authors: Finkel DM, Phillips JL, Snyder PJ Year: 1985 Journal: Journal of Clinical Endocrinology and Metabolism PMID: 3928676 Full text: https://pubmed.ncbi.nlm.nih.gov/3928676/
This landmark study established the efficacy and practical framework of combined hCG and HMG therapy for inducing spermatogenesis in men with hypogonadotropic hypogonadism — the foundational clinical evidence base for this application in males.
13 men with hypogonadotropic hypogonadism, all initially with undetectable LH and FSH, low testosterone, small testes, and azoospermia received hCG followed by addition of HMG in 12 of 13.
During therapy, all 13 achieved normal male testosterone levels. 12 of 13 had marked and continuous increase in testicular volume.
3 men developed sperm in the ejaculate with hCG alone. All but 1 patient developed sperm in their seminal fluid during combined hCG and HMG therapy.
2 men achieved 3 pregnancies, and 2 more had semen that produced positive hamster oocyte penetration assays during the protocol period.
Importantly, no differences in response to gonadotropin therapy were found between men who had received prior testosterone therapy and those who had not — directly establishing that prior testosterone treatment does not preclude successful gonadotropin-induced spermatogenesis.
The authors concluded that the prognosis for successful stimulation of spermatogenesis in hypogonadotropic hypogonadism treated with hCG/HMG is good, establishing this regimen as the standard of care for male fertility restoration in this condition.
Study 4 — Large Cohort Study: Gonadotropin Therapy in 223 Congenital Hypogonadotropic Hypogonadism Males
Authors: Liu Z, Mao J, Xing M et al. Year: 2016 Journal: PLOS ONE PMID: 26945370 Full text: https://pubmed.ncbi.nlm.nih.gov/26945370/
This large retrospective cohort of 223 male patients with congenital hypogonadotropic hypogonadism treated with combined HCG and HMG provided the most comprehensive efficacy and predictor analysis in this population at time of publication, with 5,109 person-months of follow-up.
Testicular volume increased from 2.1 plus or minus 1.6 mL at baseline to 8.1 plus or minus 4.6 mL after treatment (P less than 0.001), demonstrating substantial gonadal growth in response to gonadotropin stimulation.
Serum total testosterone rose from 0.9 plus or minus 0.5 nmol/L to 15.1 plus or minus 8.2 nmol/L (P less than 0.001) — achieving normal male testosterone levels.
64% of patients (143 of 223) successfully produced sperm. The median time to first sperm detection was 15 months (95% CI 13.5 to 16.5 months).
Of 34 patients actively attempting pregnancy, 19 successfully impregnated their partners during the treatment period.
Larger basal testicular volume (P equal to 0.012) and absence of cryptorchidism history (P equal to 0.028) were identified as independent predictors of earlier spermatogenesis — practical clinical parameters for estimating likely treatment timelines.
Study 5 — Two-Year Comparison: GnRH Pulsatile Therapy vs HCG/HMG in Isolated Hypogonadotropic Hypogonadism
Authors: Liu L, Banks SM, Barnes KM, Sherins RJ Year: 1988 Journal: Journal of Clinical Endocrinology and Metabolism PMID: 3142911 Full text: https://pubmed.ncbi.nlm.nih.gov/3142911/
This controlled comparison directly examined whether pulsatile GnRH therapy — which more closely mimics the physiological hormone secretion pattern — was superior to conventional hCG/HMG combined gonadotropin therapy for inducing testicular growth and spermatogenesis in men with complete isolated hypogonadotropic hypogonadism.
5 men received pulsatile GnRH subcutaneously every 2 hours, while 11 men received hCG (2,000 IU) plus HMG (75 IU FSH and 75 IU LH) intramuscularly three times weekly.
Mean testicular volumes after 2 years were 4.8-fold and 4.3-fold the pretreatment values in the GnRH and hCG/HMG groups respectively — not significantly different between treatment approaches.
After 24 months, sperm production had occurred in 2 of 5 GnRH-treated men (40%) and in 8 of 11 hCG/HMG-treated men (80%), though this difference was not statistically significant due to small sample size.
The authors concluded that pulsatile subcutaneous GnRH therapy for the first 2 years does not significantly accelerate or enhance testicular growth, hasten onset of sperm production, or increase sperm output compared to conventional hCG/HMG — establishing hCG/HMG as a clinically equivalent and practically more accessible alternative to pulsatile GnRH pumps.
Study 6 — Gonadotropin Review: Treatment Outcomes and Predictors in Male HH
Authors: Rohayem J et al. Year: 2020 Journal: PubMed indexed review PMID: 32445446 Full text: https://pubmed.ncbi.nlm.nih.gov/32445446/
This comprehensive review of gonadotropin therapy in male hypogonadotropic hypogonadism synthesized the evidence for combined hCG and FSH/HMG therapy, providing current context on the established efficacy data and practical clinical parameters.
The combination therapy with hCG and FSH (including HMG formulations) for a period of 12 to 24 months was found to promote testicular growth in almost all patients and spermatogenesis in approximately 80% of patients, with pregnancy rates in the range of 50%.
Gynecomastia is the most common side effect of gonadotropin therapy, attributable to hCG stimulation of aromatase leading to increased estradiol secretion.
Predictors of therapeutic success include post-pubertal onset of HH, absence of cryptorchidism history, higher baseline testicular volume, multiple prior treatment cycles, and higher baseline inhibin B concentrations.
Gonadotropin therapy is effective in promoting puberty and supporting spermatogenesis onset and preservation in HH patients with either hypothalamic or pituitary conditions — a comprehensive characterization of the breadth of male applications for hCG/HMG combined regimens.
HMG in Research Context: Male vs Female Applications
HMG occupies distinct but related roles in female and male reproductive endocrinology research.
In female fertility research, HMG is studied primarily in the context of controlled ovarian stimulation for IVF/ICSI, ovulation induction for natural conception, and the comparison of LH-containing versus FSH-only preparations across different GnRH analogue protocols. The central research question in this area is whether LH supplementation through HMG’s dual activity produces measurably superior outcomes compared to recombinant FSH alone — a question with decades of published data but still with nuance depending on patient population, GnRH protocol used, and outcome measure.
In male hypogonadism research, HMG serves as the FSH-activity-containing component of the hCG/HMG combination used to stimulate spermatogenesis in hypogonadotropic hypogonadism. Research in this application addresses the role of FSH specifically in initiating and maintaining spermatogenesis, the minimum FSH exposure required for sperm production, and comparisons between HMG-based FSH and recombinant FSH in spermatogenesis induction protocols. A key mechanistic insight from this research is that while hCG alone can initiate spermatogenesis in some patients, FSH is critical for quantitatively normal and sustained sperm production — establishing that the FSH component of HMG is mechanistically necessary for complete spermatogenesis, not merely supplementary.
Safety Context
HMG has one of the longest and most thoroughly characterized safety records of any compound in this research catalog, with decades of clinical use in millions of patients. The primary adverse effects associated with HMG-based ovarian stimulation are ovarian hyperstimulation syndrome (OHSS) — a dose and response-dependent complication of excessive follicular recruitment — and multiple pregnancy from simultaneous multi-follicle development. In males, gynecomastia from hCG-induced estradiol elevation is the most commonly reported adverse effect, manageable with aromatase inhibitor co-administration if clinically significant.
HMG preparations vary in their purity and the proportion of LH activity that derives from authentic LH versus hCG (which is present in postmenopausal urine and cross-reacts at LH receptors). Modern highly purified HMG (HP-hMG) products use immunoaffinity purification to achieve greater consistency and purity than older preparations while retaining the dual FSH and LH activity that defines the HMG class.
Current Research Status
HMG is an FDA-approved pharmaceutical used extensively in clinical reproductive medicine. Research continues actively in several areas: comparing HMG to recombinant FSH and recombinant LH combinations for optimal IVF outcomes in specific patient subpopulations, defining the role of LH activity in follicular development across different GnRH suppression protocols, optimizing spermatogenesis induction protocols in male hypogonadotropic hypogonadism, and investigating HMG in novel delivery formats. The compound has an established efficacy and safety profile but ongoing research continues to refine the clinical contexts in which dual FSH/LH activity provides advantages over FSH alone.
Reconstitution Note
HMG is supplied as a lyophilized powder. Bacteriostatic water is the standard reconstitution solvent for research use. Dissolve gently without vigorous shaking. Always confirm the recommended solvent and reconstitution protocol against the specific lot datasheet before use. Note that pharmaceutical-grade HMG formulations intended for clinical human use have specific reconstitution instructions from the manufacturer that may differ from general research-grade peptide handling guidelines.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard biological compound handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the HMG product page: https://roguecompounds.com/product/hmg/